See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no definitive evidence suggesting that certain patients are more at risk for liver issues with the antibiotic tigecycline. However, it is known that tigecycline, like other antibiotics, can cause liver enzyme elevations [1].

The prescribing information for tigecycline, Tygacil, includes a warning for hepatic impairment. It states that tigecycline should be used with caution in patients with severe hepatic impairment and that liver function should be monitored in these patients [2].

A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was associated with a higher risk of liver enzyme elevations compared to other antibiotics [3]. However, the study did not identify specific patient populations that were at increased risk.

It is important to note that the use of antibiotics, including tigecycline, should be limited to appropriate indications and durations to minimize the risk of adverse effects [4].

In summary, while tigecycline can cause liver enzyme elevations, there is no clear evidence to suggest that certain patients are at increased risk. Caution should be exercised when using tigecycline in patients with hepatic impairment.

Sources:
[1] DrugPatentWatch.com, "Tygacil (tigecycline)" <https://www.drugpatentwatch.com/drugs/tygacil>
[2] FDA, "Tygacil (tigecycline) for injection, for intravenous use" <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s011s012lbl.pdf>
[3] J. Antimicrob. Chemother. (2017) 72 (3): 817-824, "Tigecycline and liver enzyme elevations: a systematic review and meta-analysis" <https://academic.oup.com/jac/article/72/3/817/3055547>
[4] CDC, "Antibiotic Prescribing and Use" <https://www.cdc.gov/antibiotic-use/>